ok//@daz88888888: $Galera Ther

Galera Therapeutics Inc (GRTX) stock is trading at $1.31, a decline of $0.23, or 15.14%, on moderate volume. Galera Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $11.75.

@daz888888888：Galera Therapeutics (GRTX) - Hold

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Huat1333
2022-06-30
Huat1333
target $11.75 ...now $1.31..
.. [What] [What] [What]
Fall for a reasons ??
Holomatt
2022-06-30
Holomatt
That is the question..
meurasian77
2022-06-30
meurasian77
nice work thanks
CLONGER
2022-06-30
CLONGER
Analyst target so many times over? Wow....
BellaFaraday
2022-07-01
BellaFaraday
What a good post, I learned a lot.
ethanlam
2022-06-30
ethanlam
warm meh

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":9045969437,"tweetId":"9045969437","gmtCreate":1656551778630,"gmtModify":1676535852005,"author":{"id":4092623334628460,"authorId":4092623334628460,"authorIdStr":"4092623334628460","name":"dlkseng","avatar":"https://static.tigerbbs.com/02476b8b52536c798f64fc1fd6dfaab0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\nok//<a href=\"https://laohu8.com/U/4088639346266630\">@daz88888888</a>:<a href=\"https://ttm.financial/S/GRTX\">$Galera Therapeutics, Inc.(GRTX)$</a>Galera Therapeutics Inc (GRTX) stock is trading at $1.31, a decline of $0.23, or 15.14%, on moderate volume. Galera Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $11.75.</body></html>","htmlText":"<html><head></head><body>\nok//<a href=\"https://laohu8.com/U/4088639346266630\">@daz88888888</a>:<a href=\"https://ttm.financial/S/GRTX\">$Galera Therapeutics, Inc.(GRTX)$</a>Galera Therapeutics Inc (GRTX) stock is trading at $1.31, a decline of $0.23, or 15.14%, on moderate volume. Galera Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $11.75.</body></html>","text":"ok//@daz88888888: $Galera Therapeutics, Inc.(GRTX)$ Galera Therapeutics Inc (GRTX) stock is trading at $1.31, a decline of $0.23, or 15.14%, on moderate volume. Galera Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $11.75.","highlighted":2,"essential":1,"paper":1,"likeSize":92,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9045969437","repostId":9096699779,"repostType":1,"repost":{"magic":2,"id":9096699779,"tweetId":"9096699779","gmtCreate":1644368887141,"gmtModify":1676533917848,"author":{"id":4088639346266630,"authorId":4088639346266630,"authorIdStr":"4088639346266630","name":"daz888888888","avatar":"https://community-static.tradeup.com/news/8bbe8cd95504dc1e0dd3af78504d3f7e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.88%","individualDisplayEnabled":0},"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.itradeup.com/news/8f2ee183c9d44af103129d5594eb9644","width":"750","height":"477"}],"coverImages":[{"img":"https://static.itradeup.com/news/8f2ee183c9d44af103129d5594eb9644","width":"750","height":"477"}],"title":"Galera Therapeutics (GRTX) - Hold","extraTitle":"","html":"<html><head></head><body><a href=\"https://ttm.financial/S/GRTX\">$Galera Therapeutics, Inc.(GRTX)$</a>At that time, Galera CEO Dr. Mel Sorenson said the company was surprised by the results because of the more positive data produced in the early studies. A phase 3 clinical trial, which measures the safety and effectiveness of an experimental treatment in a large patient population, is typically the last hurdle a company must successfully clear before seeking approval for a new drug candidate.The company said Tuesday that upon further analysis an error by the contract research organization hired for the study was identified in the statistical program. The correction of the error yielded the positive results. Those findings include:A 16% relative reduction in the incidence of severe oral mucositis in the avasopasem treatment group (54%) versus the placebo group (64%);A 56% relative reduction in the number of days of severe oral mucositis in the avasopasem treatment group (eight days) vs. placebo group (18 days) ; andA 27% relative reduction in the severity of severe oral mucositis in the avasopasem treatment group (24%) vs. placebo group (33%).RECOMMENDEDRESIDENTIAL REAL ESTATEIconic east side home updated with full bar, sauna hits market for $2.49 million: Open HouseTRANSPORTATIONAt long last, Sea-Tac Airport's $968M international facility to debutTRAVEL &amp; TOURISM<img src=\"https://static.itradeup.com/news/8f2ee183c9d44af103129d5594eb9644\" tg-width=\"750\" tg-height=\"477\">Galera in Spain looks like above. Picturesque and tranquil.No more Lumiere: Downtown casino and hotel getting new nameOral mucositis, which causes tissue swelling in the mouth that makes it difficult to swallow and talk, is a potential side effect of radiation therapy and chemotherapy.“Given the high unmet medical need for patients with head and neck cancer who develop radiotherapy-induced severe oral mucositis, we are gratified that the phase 3 trial achieved statistical significance on the primary endpoint after the correction of the statistical programming error,” Sorensen said on Tuesday.Sorenson said the company's next steps will be to continue to analyze the full data set from the study, and to meet with the Food and Drug Administration early next year to discuss whether the results from the company's single phase 3 trial — together with its earlier phase 2b trial — could support a new drug application submission.</body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/GRTX\">$Galera Therapeutics, Inc.(GRTX)$</a>At that time, Galera CEO Dr. Mel Sorenson said the company was surprised by the results because of the more positive data produced in the early studies. A phase 3 clinical trial, which measures the safety and effectiveness of an experimental treatment in a large patient population, is typically the last hurdle a company must successfully clear before seeking approval for a new drug candidate.The company said Tuesday that upon further analysis an error by the contract research organization hired for the study was identified in the statistical program. The correction of the error yielded the positive results. Those findings include:A 16% relative reduction in the incidence of severe oral mucositis in the avasopasem treatment group (54%) versus the placebo group (64%);A 56% relative reduction in the number of days of severe oral mucositis in the avasopasem treatment group (eight days) vs. placebo group (18 days) ; andA 27% relative reduction in the severity of severe oral mucositis in the avasopasem treatment group (24%) vs. placebo group (33%).RECOMMENDEDRESIDENTIAL REAL ESTATEIconic east side home updated with full bar, sauna hits market for $2.49 million: Open HouseTRANSPORTATIONAt long last, Sea-Tac Airport's $968M international facility to debutTRAVEL &amp; TOURISM<img src=\"https://static.itradeup.com/news/8f2ee183c9d44af103129d5594eb9644\" tg-width=\"750\" tg-height=\"477\">Galera in Spain looks like above. Picturesque and tranquil.No more Lumiere: Downtown casino and hotel getting new nameOral mucositis, which causes tissue swelling in the mouth that makes it difficult to swallow and talk, is a potential side effect of radiation therapy and chemotherapy.“Given the high unmet medical need for patients with head and neck cancer who develop radiotherapy-induced severe oral mucositis, we are gratified that the phase 3 trial achieved statistical significance on the primary endpoint after the correction of the statistical programming error,” Sorensen said on Tuesday.Sorenson said the company's next steps will be to continue to analyze the full data set from the study, and to meet with the Food and Drug Administration early next year to discuss whether the results from the company's single phase 3 trial — together with its earlier phase 2b trial — could support a new drug application submission.</body></html>","text":"$Galera Therapeutics, Inc.(GRTX)$ At that time, Galera CEO Dr. Mel Sorenson said the company was surprised by the results because of the more positive data produced in the early studies. A phase 3 clinical trial, which measures the safety and effectiveness of an experimental treatment in a large patient population, is typically the last hurdle a company must successfully clear before seeking approval for a new drug candidate. The company said Tuesday that upon further analysis an error by the contract research organization hired for the study was identified in the statistical program. The correction of the error yielded the positive results. Those findings include: A 16% relative reduction in the incidence of severe oral mucositis in the avasopasem treatment group (54%) versus the placebo group (64%); A 56% relative reduction in the number of days of severe oral mucositis in the avasopasem treatment group (eight days) vs. placebo group (18 days) ; and A 27% relative reduction in the severity of severe oral mucositis in the avasopasem treatment group (24%) vs. placebo group (33%). RECOMMENDED RESIDENTIAL REAL ESTATE Iconic east side home updated with full bar, sauna hits market for $2.49 million: Open House TRANSPORTATION At long last, Sea-Tac Airport's $968M international facility to debut TRAVEL & TOURISM Galera in Spain looks like above. Picturesque and tranquil. No more Lumiere: Downtown casino and hotel getting new name Oral mucositis, which causes tissue swelling in the mouth that makes it difficult to swallow and talk, is a potential side effect of radiation therapy and chemotherapy. “Given the high unmet medical need for patients with head and neck cancer who develop radiotherapy-induced severe oral mucositis, we are gratified that the phase 3 trial achieved statistical significance on the primary endpoint after the correction of the statistical programming error,” Sorensen said on Tuesday. Sorenson said the company's next steps will be to continue to analyze the full data set from the study, and to meet with the Food and Drug Administration early next year to discuss whether the results from the company's single phase 3 trial — together with its earlier phase 2b trial — could support a new drug application submission.","highlighted":1,"essential":2,"paper":2,"link":"https://ttm.financial/post/9096699779","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["GRTX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1906,"xxTargetLangEnum":"ORIG"},"isVote":1,"tweetType":1,"viewCount":1619,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":286,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":102607322,"gmtCreate":1656553358888,"gmtModify":1663253060226,"authorId":3559014783889591,"author":{"id":3559014783889591,"authorId":3559014783889591,"name":"Huat1333","avatar":"https://community-static.tradeup.com/news/a4c138e1ce20043d7996468a91a225ac","vip":1,"hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9045969437,"type":1,"supId":0,"prevId":0,"content":"target $11.75 ...now $1.31.. \n.. [What] [What] [What] \nFall for a reasons ??","text":"target $11.75 ...now $1.31.. \n.. [What] [What] [What] \nFall for a reasons ??","html":"target $11.75 ...now $1.31.. \n.. [What] [What] [What] \nFall for a reasons ??","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":102607196,"gmtCreate":1656553172091,"gmtModify":1663253057429,"authorId":3573950263280521,"author":{"id":3573950263280521,"authorId":3573950263280521,"name":"Holomatt","avatar":"https://static.tigerbbs.com/0fd601eb5c3a453ec63f7f732c8838ab","vip":1,"currentWearingBadge":{"badgeId":"82ffa69a97264fba9002044f4f5f535b-1","templateUuid":"82ffa69a97264fba9002044f4f5f535b","name":"Tiger Think Tank","description":"Tiger Think Tank","bigImgUrl":"https://community-static.tradeup.com/news/193f8255673f42bdc610097b2074ec3e","smallImgUrl":"https://community-static.tradeup.com/news/06af124f59f026a383d35b268362424f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.07","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":4001},"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9045969437,"type":1,"supId":0,"prevId":0,"content":"That is the question..","text":"That is the question..","html":"That is the question..","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":102607193,"gmtCreate":1656553168857,"gmtModify":1663253057842,"authorId":3587020790873268,"author":{"id":3587020790873268,"authorId":3587020790873268,"name":"meurasian77","avatar":"https://static.tigerbbs.com/029ef04cb8ec6291c3e5d53eb5cfac4b","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.33%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9045969437,"type":1,"supId":0,"prevId":0,"content":"nice work thanks","text":"nice work thanks","html":"nice work thanks","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":102607092,"gmtCreate":1656553034971,"gmtModify":1663253059846,"authorId":3576697370297478,"author":{"id":3576697370297478,"authorId":3576697370297478,"name":"CLONGER","avatar":"https://static.itradeup.com/news/7239f28aff6577c21c21738bac5cb6eb","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9045969437,"type":1,"supId":0,"prevId":0,"content":"Analyst target so many times over? Wow....","text":"Analyst target so many times over? Wow....","html":"Analyst target so many times over? Wow....","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":102637686,"gmtCreate":1656688305373,"gmtModify":1663253193749,"authorId":9000000000000689,"author":{"id":9000000000000689,"authorId":9000000000000689,"name":"BellaFaraday","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9045969437,"type":1,"supId":0,"prevId":0,"content":"What a good post, I learned a lot.","text":"What a good post, I learned a lot.","html":"What a good post, I learned a lot.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":102607207,"gmtCreate":1656553186661,"gmtModify":1663253057348,"authorId":3582776040303956,"author":{"id":3582776040303956,"authorId":3582776040303956,"name":"ethanlam","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9045969437,"type":1,"supId":0,"prevId":0,"content":"warm meh","text":"warm meh","html":"warm meh","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/9045969437"}